Get the Stockscreener App
14.44
0.80%
0.115
Atara Biotherapeutics Inc stock is traded at $14.44, with a volume of 3,218.
It is up +0.80% in the last 24 hours and up +19.14% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
See More
Previous Close:
$14.32
Open:
$14.62
24h Volume:
3,218
Relative Volume:
0.06
Market Cap:
$101.41M
Revenue:
$100.44M
Net Income/Loss:
$-133.16M
P/E Ratio:
-0.5606
EPS:
-25.76
Net Cash Flow:
$-94.85M
1W Performance:
+3.29%
1M Performance:
+19.14%
6M Performance:
+161.12%
1Y Performance:
+79.83%
1-Day Range:
$14.30
$14.68
1-Week Range:
$13.89
$16.72
52-Week Range:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
14.44 | 100.60M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Can you recover from losses in Atara Biotherapeutics Inc.July 2025 Movers & Comprehensive Market Scan Insights - newser.com
Chart based exit strategy for Atara Biotherapeutics Inc.Market Activity Summary & Safe Investment Capital Preservation Plans - newser.com
Using economic indicators to assess Atara Biotherapeutics Inc. potentialJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com
Will Atara Biotherapeutics Inc. continue its uptrendWeekly Risk Summary & Precise Buy Zone Tips - newser.com
What hedge fund activity signals for Atara Biotherapeutics Inc. stockJuly 2025 Volume & Capital Efficient Trading Techniques - newser.com
How rising interest rates impact Atara Biotherapeutics Inc. stockRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Atara Biotherapeutics' (ATRA) "Sell (D+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 30% Though Its Price And Business Still Lag The Industry - simplywall.st
Atara Biotherapeutics Inc. stock trendline breakdownQuarterly Profit Report & Comprehensive Market Scan Insights - newser.com
Statistical indicators supporting Atara Biotherapeutics Inc.’s strengthJuly 2025 Rallies & Verified Momentum Stock Ideas - newser.com
Pattern recognition hints at Atara Biotherapeutics Inc. upside2025 Momentum Check & Reliable Entry Point Trade Alerts - newser.com
Atara Biotherapeutics Inc Stock Analysis and ForecastAutomated Trading Signals & Your Free Entry to Smart Investing Starts Here - earlytimes.in
How Atara Biotherapeutics Inc. stock reacts to global recession fearsWeekly Loss Report & Accurate Technical Buy Alerts - newser.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $21.00 Consensus Price Target from Brokerages - Defense World
How Atara Biotherapeutics Inc. (AT20) stock stacks up against competitorsNew Guidance & Real-Time Market Trend Scan - newser.com
Is Atara Biotherapeutics Inc. stock positioned for long term growthPortfolio Value Report & Expert Verified Stock Movement Alerts - newser.com
What drives Atara Biotherapeutics Inc stock priceStock Price Divergence & Low Entry Capital Stocks - earlytimes.in
Can swing trading help recover from Atara Biotherapeutics Inc. losses2025 Top Decliners & Technical Entry and Exit Alerts - newser.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership - Yahoo Finance
Cancer stocks rebound, outpacing broader markets in Q3 2025 - BioWorld MedTech
Analyzing net buyer seller activity in Atara Biotherapeutics Inc.Quarterly Investment Review & Reliable Volume Spike Alerts - newser.com
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - inkl
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Forecasting Atara Biotherapeutics Inc. price range with options dataQuarterly Profit Review & Step-by-Step Trade Execution Guides - newser.com
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atara Biotherapeutics Inc Stock (ATRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
Aug 18 '25 |
Sale |
11.61 |
1,809 |
21,009 |
35,258 |
| Panacea Innovation Ltd | 10% Owner |
Aug 15 '25 |
Buy |
12.19 |
55,000 |
670,422 |
1,405,000 |
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):